美国 · SEC FORM 4
Kailera Therapeutics, Inc.
KLRA · Nasdaq · CIK 0002096997 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
1 同一窗口内观察到的 Form 4 交易行
0 sales · 1 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
最新留档分数
- 84.4
- 84.4
- 84.4
- 84.4
- 84.4
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -22.1%
- 3M
- -41.9%
- 6M
- —
- 12M
- —
波动率与流动性
- 波动率
- 71.8%
- Beta
- —
- 平均每日成交额
- USD 10.4M
估值
- 市值
- USD 1.5B
- P/E
- —
基本面
- 利润率
- —
- ROE
- —
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-06 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 8,683,381
- 上期报告
- 5,962,752
- 日均成交量
- 1,545,459
- 回补天数
- 5.6
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | 买入 (P) | Common Stock | 500,000 | USD 16.00 | USD 8,000,000 | SEC 申报 ↗ |
| 2026-04-20 | Koppel Adam | 买入 (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC 申报 ↗ |
| 2026-04-20 | Kaplan Andrew T. | 买入 (P) | Common Stock | 8,398,438 | USD 16.00 | USD 134,375,008 | SEC 申报 ↗ |
| 2026-04-20 | BCLS Fund IV Investments GP, LLC; BCLS Fund IV Investments, L.P.; Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC | 买入 (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC 申报 ↗ |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC; BCPE Perseus Investor GP, LLC; BCPE Perseus Investor, LP; Bain Capital Fund XIV, L.P.; Bain Capital XIV General Partner, LLC | 买入 (P) | Common Stock | 8,398,438 | USD 16.00 | USD 134,375,008 | SEC 申报 ↗ |
Form 4 申报证据
15 transaction lines in the latest 365-day window; 15 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-09 | Renaud Ronald C JR | 期权行权／转换 (M) | Common Stock | 38,094 | USD 5.25 | USD 199,994 | SEC 申报 ↗ |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | 买入 (P) | Common Stock | 500,000 | USD 16.00 | USD 8,000,000 | SEC 申报 ↗ |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | C (C) | Common Stock | 10,276,820 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (12 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-09 | Renaud Ronald C JR | 期权行权／转换 (M) | Common Stock | 38,094 | USD 5.25 | USD 199,994 | SEC 申报 ↗ |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | 买入 (P) | Common Stock | 500,000 | USD 16.00 | USD 8,000,000 | SEC 申报 ↗ |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | C (C) | Common Stock | 10,276,820 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | C (C) | Common Stock | 11,511,852 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Koppel Adam | 买入 (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC 申报 ↗ |
| 2026-04-20 | Koppel Adam | C (C) | Common Stock | 21,020,768 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Kaplan Andrew T. | 买入 (P) | Common Stock | 8,398,438 | USD 16.00 | USD 134,375,008 | SEC 申报 ↗ |
| 2026-04-20 | Kaplan Andrew T. | C (C) | Common Stock | 17,857,143 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | BCLS Fund IV Investments GP, LLC; BCLS Fund IV Investments, L.P.; Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC | 买入 (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC 申报 ↗ |
| 2026-04-20 | BCLS Fund IV Investments GP, LLC; BCLS Fund IV Investments, L.P.; Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC | C (C) | Common Stock | 21,020,768 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC; BCPE Perseus Investor GP, LLC; BCPE Perseus Investor, LP; Bain Capital Fund XIV, L.P.; Bain Capital XIV General Partner, LLC | 买入 (P) | Common Stock | 8,398,438 | USD 16.00 | USD 134,375,008 | SEC 申报 ↗ |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC; BCPE Perseus Investor GP, LLC; BCPE Perseus Investor, LP; Bain Capital Fund XIV, L.P.; Bain Capital XIV General Partner, LLC | C (C) | Common Stock | 17,857,143 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | KLRA |
| CIK | 0002096997 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 15 transaction lines from 2026-04-20 to 2026-06-09 5 P purchase lines · 0 S sale lines · 10 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.